Lundbeck is a global pharmaceutical company highly committed to improving the quality of life for people suffering from brain diseases. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The companys products... More
Wednesday, Jun 198:04 AMEU antitrust regulators have fined nine drug makers a combined €146M for blocking the supply of cheaper drugs through "pay-for-delay" deals in which brand name companies pay generic manufacturers not to enter the market with their products. Denmark's Lundbeck (HLUKF.PK) received the biggest penalty of €94M. The punishment highlights how authorities on both sides of the Atlantic are coming down on "pay for delay," with the U.S. Supreme Court recently ruling that the FTC can take action against such deals. |Wednesday, Jun 198:04 AM| Comment!
Monday, Jun 38:04 AMThe EU reportedly intends to levy a "significant" fine on Lundbeck (HLUYY.PK) for limiting access to cheaper drugs through "pay for delay" deals in which brand name companies pay generic manufacturers not to enter the market with their products. The EU also plans to impose lighter penalties on Merck KGaA (MKGAF.PK) and seven smaller generic firms. The issue has aroused much controversy in the U.S., where a case has been heard by the Supreme Court. |Monday, Jun 38:04 AM| Comment!
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.